home / press / releases

Menu
  • Search all tables

releases: https://quigley.house.gov/media-center/press-releases/quigleys-bill-reauthorizing-act-als-passes-senate

One row per release. Full-text search runs over title + body text.

Data license: MIT · Data source: dwillis/congress-press

This data as json

url title date year month party chamber state member_name bioguide_id domain scraper source date_source text has_text collected_at updated_at
https://quigley.house.gov/media-center/press-releases/quigleys-bill-reauthorizing-act-als-passes-senate Quigley's Bill Reauthorizing the ACT for ALS Passes the Senate 2026-09-29 2026 2026-09 Democrat House IL Mike Quigley Q000023 quigley.house.gov quigley https://quigley.house.gov/media-center/press-releases scraper Yesterday, the Senate passed the Access to Critical Therapies for ALS Reauthorization Act (ACT for ALS Reauthorization Act) of 2026 with bipartisan support. Led by Representatives Mike Quigley (IL-05) and Ken Calvert (CA-41) in the House and Senators Lisa Murkowski (R-AK) and Chris Coons (D-DE) in the Senate, the ACT for ALS Reauthorization Act will renew programs from the 2021 ACT for ALS, which advanced scientific understanding of neurodegenerative diseases and helped people living with ALS access promising new treatments. “Since 2021, the ACT for ALS has helped thousands of Americans access the promising treatments and research they need,” said Rep. Mike Quigley (IL-05), lead sponsor of the bill. “But there is still no cure for ALS, making it a 100% fatal disease. We need the federal government to reauthorize the ACT for ALS immediately to continue funding ALS research. I’m proud of my colleagues in the Senate for passing this bill and continuing our work." The ACT for ALS Reauthorization Act will also codify the Department of Health and Human Services’ (HHS) interpretation of Expanded Access Program eligibility guidelines and require the FDA to create a new 5-year Action Plan for rare neurodegenerative diseases. This legislation has been endorsed by I AM ALS, the Muscular Dystrophy Association, the ALS Association, and the ALS Network. “Since my diagnosis almost nine years ago, our community has fought fiercely for change,” said I AM ALS co-founder Brian Wallach. “Thanks to the leadership of the I AM ALS movement, federal research funding has grown exponentially, helping us get closer to a cure. We’re deeply grateful to our champions in Congress—including cosponsors Senators Coons (D-DE) and Murkowski (R-AK) and Representatives Quigley (D-IL-05) and Calvert (R-CA-41)—and all the tireless advocates who made sure this vital bill was renewed.” 1 2026-10-01T11:23:28Z 2026-10-01T11:25:15Z
Powered by Datasette · Queries took 1.411ms · Data license: MIT · Data source: dwillis/congress-press